1. Introduction

According to the World Anti-Doping Code (WADC), doping is defined as a violation of the Anti-Doping Rules ^[1], comprising, inter alia, the detection of a prohibited substance, its metabolites, or markers in the blood or urine sample of an athlete. However, there are different scenarios where such an Adverse Analytical Finding (AAF) does not necessarily result from a deliberate application of a performance-enhancing/banned drug. Such cases of inadvertent doping include the ingestion of adulterated or faked dietary supplements, tainted food, and contaminated drugs, as well as passive exposure to doping agents or an insufficient education of the athletes with regards to changes of the Prohibited List annually revised by the World Anti-Doping Agency (WADA) ^{[2][3][4][5][6]}. According to WADA’s policy of strict liability, an athlete is responsible for the substances found in his/her doping control samples and anti-doping rule violations (ADRVs) occur regardless of his/her intention ^[1][7]. Possible consequences comprise not only temporary or permanent suspensions, but also loss of medals and/or records, financial sanctions, damage to the athlete’s reputation, and failed sponsorships ^[3][8]. However, the decision-making processes are flexible to consider the circumstances, so that clear evidence about the origin of the detected prohibited substance can potentially lead to reduced sanctions ^[1][4][7]. On the other hand, it cannot be excluded that athletes occasionally argue with contamination scenarios in an attempt to excuse an AAF in order to avoid impending penalties ^[2][5]. Consequently, a careful interpretation of the results and, if available, additional data (e.g., from microdose elimination studies) are necessary and desirable.

2. Dietary Supplements

Since ancient times, athletes try to improve their strength, speed, agility, and bravery by using special diets and products such as lion hearts and deer livers ^[6][9]. With the growing scientific understanding of exercise physiology in the early 20th century, more specialized dietary supplements and ergogenic aids were employed to increase physical fitness ^[9]. In general, athletic performance depends on a variety of factors such as talent, motivation, training, and the resistance to injuries, but the individual potential can be optimized by a healthy and appropriate diet ^[8][10][11]. An additional application of dietary supplements can be reasonable for athletes with nutritional challenges (e.g., vegans) or in certain medical circumstances (e.g., a diagnosed nutrient deficiency); however, for many of them, health and performance enhancing effects are not proven ^{[6][8][10][12][13]}. Therefore, they should only be used after consultation of a physician or sports nutritionist ^[8][10]. Nevertheless, supplement use is nowadays widespread among athletes at all levels of sport, especially as they are readily available without medical prescription ^[8][13].

Athletes using dietary supplements are not only susceptible to acute or long-term damage to their health but also to inadvertent doping ^[8][10]. While the safety, purity, and efficacy of pharmaceutical products are thoroughly and continuously controlled, no uniform regulations and quality controls exist for the manufacturing of dietary supplements, resulting in a highly variable quality of the available preparations ^{[2][10][14][15][16][17]}. The main problem for the general population and especially for athletes is an inaccurate labelling of ingredients, which is of concern to all types of dietary supplements including pills, powders, capsules, and liquids ^{[2][8][10][14][15][18][19][20]}. While especially those products featuring comparably expensive components occasionally contain only little (if any) active ingredient ^[10][14], dietary supplements cross-contaminated or even intentionally fortified with undeclared performance-enhancing substances such as anabolic agents or stimulants in order to increase their efficacy are significantly more worrying ^{[2][8][15][18][21]}. Moreover, the use of varying (chemical) synonyms of prohibited substances on product labels adds another level of complexity for athletes to recognize a potential issue ^[2][8][19]. Cross-contaminations are commonly the result of one of two scenarios: Either inappropriately cleaned containers are used for the transportation or storage of the raw materials or dietary supplements, especially when other preparations such as prohormones are manufactured in the same production line ^{[10][15][18][21][22][23]}. Even though selected reputable manufacturers, working according to Good Manufacturing Practicing (GMP) regulations, have identified risk factors and installed quality controls accordingly, the situation is further complicated by the fact that the source of some cross-contaminations is not necessarily the facility, where the final products are manufactured ^[22]. Therefore, product and/or raw material testing needs to be conducted with assays that are applicable to all types of relevant matrices and have limits of detection (LODs) in the low ng/g or parts per billion (ppb) range. Such sensitivities are necessary to account for the excellent detection limits of currently employed analytical methods in sports drug testing and the facts that for many substances any detected amount constitutes an AAF in routine doping controls with some dietary supplements being administered in relatively large amounts ^{[6][18][21][22]}. Moreover, batch-to-batch, package-to-package, and even tablet-to-tablet variations can occur. Even if the resulting concentrations of a prohibited drug are too low to have any physiological effect, they can cause an AAF in sports ^[8][18][21]. Therefore, athletes are advised to use available sources to identify “low-risk” products and prevent unintentional ADRVs due to the administration of contaminated/adulterated dietary supplements ^[15]. 

3. Contaminations of Drugs and Medical Preparations

Both pharmaceuticals and food are usually tested for the presence of contaminations and impurities at the part per million (ppm) level, which is sufficient to prevent any pharmacological effects, but it cannot rule out entirely implications for sports drug testing ^[21]. For example, the diuretic HCTZ was detected in the in-competition urine sample of a Swiss athlete at an estimated concentration of 5 ng/mL at the end of 2014 ^[24]. The athlete had not declared the use of any dietary supplement, but the administration of several tablets containing ibuprofen, a non-steroidal anti-inflammatory drug (NSAID). Surprisingly, the analysis of the ingested analgesic as well as the respective retention sample provided by the manufacturer demonstrated the presence of HCTZ at a concentration of approximately 2 µg per tablet. According to the pharmaceutical company producing the NSAID, the contamination was located in the coating of the tablets and no indications could be found that the 10 ppm cleaning limit defined by current GMP guidelines was exceeded. In order to test the plausibility of the suspected scenario of inadvertent doping, two administration studies with placebo-tablets containing 2.5 µg of HCT were conducted and the collected post-administration samples were found to contain HCTZ at concentrations of up to 16 ng/mL. As these findings supported an accidental ingestion of the doping agent by the athlete, no sanction was imposed.

4. Food Contaminations

Besides dietary supplements and medical preparations, also food was found to be a potential source of inadvertent doping. In several countries such as China and Mexico, the sympathomimetic and anabolic agent clenbuterol has been illegally used as growth promoter in animal production ^[25][26]. As a result, the edible meat is notably lean but was also found to be contaminated with clenbuterol residues, which can pose a health risk for the consumer and lead to AAFs in sports. Due to its anabolic and lipolytic effects, clenbuterol is listed among the anabolic agents in the WADA Prohibited List and is therefore prohibited both in- and out-of-competition ^[26][27][28]. In routine sports drug testing, clenbuterol can be detected in urine down to concentrations of a few pg/mL by using LC-MS approaches ^[26][28]. Until the amendment of Article 7.4 of the WADC in 2019, where the option to report atypical findings for clenbuterol if observed below 5 ng/mL of urine was introduced ^[1][29], no threshold applied for the detection of this drug in doping control samples, and even low concentrations resulted in AAFs and corresponding sanctions ^[28][30]. In an administration study with meat obtained from calves that were treated with clenbuterol at a dosage of 2 × 5 g/kg over a period of 37/43 days, the consumption by healthy volunteers resulted in urinary drug concentrations of up to 850 pg/mL in some of the participant’s urine samples ^[31]. Although the misuse of clenbuterol in food-producing animals is strictly regulated in most countries, several cases of clenbuterol intoxication following meat consumption have been reported from all over the world ^[25][28][32]. Symptoms can include tremors, tachycardia, palpitations, hypokalemia, nausea, headache, nervousness, dizziness, fever, chills, peripheral vasodilatation, and—in acute cases—breathing interruptions.

This entry is adapted from the peer-reviewed paper 10.3390/foods9081012